Pfizer vaccine closer to getting the OK in U.S.
WASHINGTON — U.S. regulators Tuesday released their first scientific evaluation of Pfizer’s COVID-19 vaccine and confirmed it offers strong protection, setting the stage for the government to green light the biggest vaccination effort in the nation’s history.
The analysis by Food and Drug Administration scientists comes ahead of a Thursday meeting where the agency’s independent advisers will debate if the evidence is strong enough to recommend vaccinating millions of Americans. A final FDA decision and the first shots could follow within just days.
They are among a whirlwind of developments that are expected to make multiple vaccines available by early next year, in the U.S. and beyond.
Britain on Tuesday began vaccinations with the shot made by Pfizer and German partner BioNTech. The FDA later this month will consider one developed by Moderna. Also Tuesday, a medical journal published early data suggesting a third vaccine candidate, AstraZeneca’s, also protects people, though not as much as the two other frontrunners.
The vaccines emerged from an all-out worldwide race and are reaching the market less than a year after the virus was even identified — a remarkable scientific achievement that shaved years off the usual process.
The encouraging developments come as the coronavirus continues surging across much of the world. The scourge has claimed more than 1.5 million lives, including over 285,000 in the U.S., the highest toll of any country.
FDA scientists reanalyzed data from Pfizer’s huge, still-unfinished study and found that so far, the vaccine appears safe and more than 90% effective across patients of different ages, races and underlying health conditions. The FDA specifically confirmed it works well in older people, who are especially vulnerable to the virus.
Thursday’s public meeting will be closely watched by health authorities around the world and is considered key to bolstering confidence in the shots amid skepticism about vaccine safety among many Americans.